Sökning: id:"swepub:oai:gup.ub.gu.se/112878" >
Long-term results o...
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer.
-
- Arriagada, Rodrigo (författare)
- Karolinska Institutet
-
Dunant, Ariane (författare)
-
Pignon, Jean-Pierre (författare)
-
visa fler...
-
- Bergman, Bengt, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
-
Chabowski, Mariusz (författare)
-
Grunenwald, Dominique (författare)
-
Kozlowski, Miroslaw (författare)
-
Le Péchoux, Cécile (författare)
-
Pirker, Robert (författare)
-
Pinel, Maria-Izabel Sathler (författare)
-
Tarayre, Michèle (författare)
-
Le Chevalier, Thierry (författare)
-
visa färre...
-
(creator_code:org_t)
- 2010
- 2010
- Engelska.
-
Ingår i: Journal of clinical oncology. - 1527-7755. ; 28:1, s. 35-42
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE Based on 5-year or shorter-term follow-up data in recent randomized trials, adjuvant cisplatin-based chemotherapy is now generally recommended after complete surgical resection for patients with non-small-cell lung cancer (NSCLC). We evaluated the results of the International Adjuvant Lung Cancer Trial study with three additional years of follow-up. PATIENTS AND METHODS Patients with completely resected NSCLC were randomly assigned to three or four cycles of cisplatin-based chemotherapy or to observation. Cox models were used to evaluate treatment effect according to follow-up duration. Results The trial included 1,867 patients with a median follow-up of 7.5 years. Results showed a beneficial effect of adjuvant chemotherapy on overall survival (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.02; P = .10) and on disease-free survival (HR, 0.88; 95% CI, 0.78 to 0.98; P = .02). However, there was a significant difference between the results of overall survival before and after 5 years of follow-up (HR, 0.86; 95% CI, 0.76 to 0.97; P = .01 v HR, 1.45; 95% CI, 1.02 to 2.07; P = .04) with P = .006 for interaction. Similar results were observed for disease-free survival. The analysis of non-lung cancer deaths for the whole period showed an HR of 1.34 (95% CI, 0.99 to 1.81; P = .06). CONCLUSION These results confirm the significant efficacy of adjuvant chemotherapy at 5 years. The difference in results beyond 5 years of follow-up underscores the need for the long-term follow-up of other adjuvant lung cancer trials and for a better identification of patients deriving long-term benefit from adjuvant chemotherapy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- Antineoplastic Combined Chemotherapy Protocols
- therapeutic use
- Carcinoma
- Non-Small-Cell Lung
- drug therapy
- mortality
- Cause of Death
- Cisplatin
- administration & dosage
- Disease-Free Survival
- Female
- Humans
- Lung Neoplasms
- drug therapy
- mortality
- Male
- Middle Aged
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Arriagada, Rodri ...
-
Dunant, Ariane
-
Pignon, Jean-Pie ...
-
Bergman, Bengt, ...
-
Chabowski, Mariu ...
-
Grunenwald, Domi ...
-
visa fler...
-
Kozlowski, Miros ...
-
Le Péchoux, Céci ...
-
Pirker, Robert
-
Pinel, Maria-Iza ...
-
Tarayre, Michèle
-
Le Chevalier, Th ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Journal of clini ...
- Av lärosätet
-
Göteborgs universitet
-
Karolinska Institutet